SCHEMBL6548310

SCHEMBL6548310

CCON=C(C)c1ccc(OCCCCCOc2c(Cl)cc(OCC=C(Cl)Cl)cc2Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.38
GAA P10253 3/20 0.36
FURIN P09958 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
RAD52 P43351 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
TP53 P04637 2/20 0.34
MAPT P10636 2/20 0.34
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34
ALOX15 P16050 1/20 0.34
RAB9A P51151 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TSHR P16473 1/20 0.33
PLA2G4B P0C869 1/20 0.33
SLC2A1 P11166 2/20 0.32
POLB P06746 1/20 0.32
APEX1 P27695 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6549633 1.00 HTT (0.38) HTTGAAFURINMEN1KMT2A
SCHEMBL6548597 0.99 HTT (0.39) HTTGAAFURINMEN1KMT2A
SCHEMBL6548681 0.97 HTT (0.39) HTTGAAFURINMEN1KMT2A
SCHEMBL6547864 0.96 HTT (0.39) HTTGAAFURINMEN1KMT2A
SCHEMBL6547887 0.94 HTT (0.39) HTTGAAFURINMEN1KMT2A
SCHEMBL6548389 0.93 HTT (0.37) HTTGAAFURINMEN1KMT2A
SCHEMBL6548442 0.92 HTT (0.39) HTTGAAFURINSMN1; SMN2L3MBTL1
SCHEMBL6548268 0.89 HTT (0.39) HTTGAAFURINMEN1KMT2A
SCHEMBL6549146 0.89 HTT (0.36) HTTGAAFURINSMN1; SMN2L3MBTL1
SCHEMBL6548572 0.88 NPC1 (0.39) HTTSMN1; SMN2NPC1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0975586-B1 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL CO (JP) 2004-12-01 EP disclosed
US-6448444-B2 INSECTICIDES, MITICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-09-10 US disclosed
US-6437184-B1 INSECTICIDES, ACARICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-08-20 US disclosed
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production SUMITOMO CHEMICAL COMPANY, LIMITED 2002-02-14 US disclosed
EP-0975586-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION Sumitomo Chemical Company, Limited (JP) 2000-02-02 EP disclosed
WO-1998045254-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production CBR3, CBR1, NOX3 HTT 4052/4885GAA 3855/4885FURIN 3892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.